Abbott Receives FDA Approval for Navitor TAVI System
Abbott's new Navitor device features advancements to improve patient care, including reducing or eliminating risk of blood leakage around valve implant
Stay updated with breaking news from Abbott Flexnav. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Abbott's new Navitor device features advancements to improve patient care, including reducing or eliminating risk of blood leakage around valve implant
NORTH CHICAGO (dpa-AFX) - Abbott Laboratories (ABT) announced Tuesday that the U.S. Food and Drug Administration (FDA) has approved the company's latest-generation transcatheter aortic valve implantation
Abbott (NYSE:ABT) announced today that it received FDA approval for its latest-generation transcatheter aortic valve implant (TAVI) system.
Abbott has announced it has received the CE Mark for its latest-generation transcatheter aortic valve implantation (TAVI) system, Navitor™, making the minimally invasive device available for people in Europe with severe aortic stenosis who are at high or extreme surgical risk.
Abbott today announced it has received CE Mark for its latest-generation transcatheter aortic valve implantation system, Navitor™, making the minimally invasive device available for people in Europe with severe aortic stenosis who are at high or extreme surgical risk. With the Navitor valve, the company is advancing TAVI therapies with innovations including a unique design to prevent blood leaking around the … Abbott (NYSE: ABT) today announced it has received CE Mark for its latest-generation transcatheter aortic valve implantation (TAVI) system, Navitor™, making the minimally invas...